Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • cleoho175
    Junior Member
    • Nov 2010
    • 5

    Using PHRAP to assemble 454 contigs and Sanger reads

    Hi all,

    I'm a beginner in sequence assembly and have a question about using the assembler, PHRAP.

    I'm trying to use PHRAP to assemble 454 contigs (generated by MIRA) and Sanger reads. However, PHRAP requires its input to follow the St. Louis naming convention, and my 454 contigs clearly do not conform to this system since they are outputs from MIRA; also, they don't contain any info that allows me to convert their names to St. Louis names.

    Has anyone encountered similar problems before? And how did one resolve naming issue like this?

    Thanks.
  • sklages
    Senior Member
    • May 2008
    • 628

    #2
    Hi,

    - naming schemes are usually applied if you need to put forward/reverse reads into relation (template name, insert size etc). This is probably not important for your contigs. These are unordered (MIRA doesn't do any scaffolding) pieces of sequence of different sizes ...

    - why don't you use MIRA for a hybrid 454/sanger assembly?

    - why don't you use Roche's newbler (2.5) for a hybrid 454/sanger assembly?
    (OK, you need to have access to Roche software).

    cheers,
    Sven

    Comment

    • cleoho175
      Junior Member
      • Nov 2010
      • 5

      #3
      Hi Sven,

      I have done a 454/sanger hybrid assembly with the reads in MIRA. Now I'm trying assemble the 454 contigs and sanger reads to see its difference between the hybrid trial.

      And since MIRA does not output an TRACEINFO XML file for my 454 contigs, I don't have the required input for another trial in MIRA; this is why I chose PHRAP because it needs only the fasta and fasta quality files.

      But now I'm having problems with the naming.....so as you said, if the direction isn't important for my contigs, can I input my contigs into PHRAP without conforming to the naming? (PHRAP manual doesn't recommend to do so..?)

      Comment

      • sklages
        Senior Member
        • May 2008
        • 628

        #4
        As you have all input data, you are probably more successful if use all data in a hybrid approach.

        Nevertheless, no need to use phrap, MIRA knows the switch "--notraceinfo" or if you need to handle chemistries differently, "merge_xmltraceinfo=yes/no". Have alook at the docs accordingly.

        cheers,
        Sven

        Comment

        • Torst
          Senior Member
          • Apr 2008
          • 275

          #5
          Originally posted by cleoho175 View Post
          I'm trying to use PHRAP to assemble 454 contigs (generated by MIRA) and Sanger reads.
          You may want to considere CAP3 or wgs-assembler / Arache too.

          Comment

          • cleoho175
            Junior Member
            • Nov 2010
            • 5

            #6
            Originally posted by sklages View Post
            As you have all input data, you are probably more successful if use all data in a hybrid approach.

            Nevertheless, no need to use phrap, MIRA knows the switch "--notraceinfo" or if you need to handle chemistries differently, "merge_xmltraceinfo=yes/no". Have alook at the docs accordingly.

            cheers,
            Sven
            I asked Bastien Chevreux (the developer of MIRA) about assembling my contigs in MIRA, and he doesn't suggest doing so because the 454 contigs may be too long for MIRA to handle. So I guess the question goes back to whether one can input contigs into PHRAP without naming it properly according to the St. Louis convention.

            As you said before, it probably doesn't matter because my contigs are unordered (I concur to this point of view). But since I don't know the consequences of disobeying the convention, I'm afraid that inputting the contigs into PHRAP will just completely crash the program :S

            Comment

            • cleoho175
              Junior Member
              • Nov 2010
              • 5

              #7
              Originally posted by Torst View Post
              You may want to considere CAP3 or wgs-assembler / Arache too.
              Thanks for the suggestion!

              Comment

              • Torst
                Senior Member
                • Apr 2008
                • 275

                #8
                Originally posted by cleoho175 View Post
                So I guess the question goes back to whether one can input contigs into PHRAP without naming it properly according to the St. Louis convention. But since I don't know the consequences of disobeying the convention, I'm afraid that inputting the contigs into PHRAP will just completely crash the program :S
                I'm pretty sure you won't crash phrap if you disobey the convention. I've fed it arbitrary .fasta files before. Surely you can just do a simple test anyway to check?

                The Phrap manual "phrap.doc" describes the various St.Louis suffixes:

                "s" forward direction read on single stranded (SS) template, dye primer chemistry
                "f" forward read on double stranded (DS) template, dye primer chemistry[LIST]
                "r" DS reverse read, dye primer chemistry
                "x" SS forward read, standard dye terminator chemistry
                "z" DS forward read, standard dye terminator chemistry
                "y" DS reverse read, standard dye terminator chemistry
                "i" SS forward read, big dye terminator chemistry
                "b" DS forward read, big dye terminator chemistry
                "g" DS reverse read, big dye terminator chemistry
                "t" for T7 (cDNAs)
                "p" for SP6 (cDNAs)
                "e" for T3 (cDNAs)
                "d" for special
                "c" consensus pieces
                "a" assembly pieces

                As you want to feed it existing contigs, just use ".c" or ".a" suffixes on your read IDs. That's what I've done in the past.

                Comment

                • cleoho175
                  Junior Member
                  • Nov 2010
                  • 5

                  #9
                  I'll give it a try. Thanks so much for the help! I'll report back the results.

                  Comment

                  Latest Articles

                  Collapse

                  • SEQadmin2
                    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                    by SEQadmin2


                    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                    The systematic characterization of the human proteome has
                    ...
                    07-20-2026, 11:48 AM
                  • SEQadmin2
                    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                    by SEQadmin2



                    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                    ...
                    07-09-2026, 11:10 AM
                  • SEQadmin2
                    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                    by SEQadmin2



                    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                    07-08-2026, 05:17 AM

                  ad_right_rmr

                  Collapse

                  News

                  Collapse

                  Topics Statistics Last Post
                  Started by SEQadmin2, Today, 12:17 PM
                  0 responses
                  10 views
                  0 reactions
                  Last Post SEQadmin2  
                  Started by SEQadmin2, Yesterday, 11:41 AM
                  0 responses
                  11 views
                  0 reactions
                  Last Post SEQadmin2  
                  Started by SEQadmin2, 07-20-2026, 11:10 AM
                  0 responses
                  23 views
                  0 reactions
                  Last Post SEQadmin2  
                  Started by SEQadmin2, 07-13-2026, 10:26 AM
                  0 responses
                  37 views
                  0 reactions
                  Last Post SEQadmin2  
                  Working...